Our
Pipeline

AVROBIO is studying the safety and efficacy of its investigational gene therapy in individuals with Gaucher disease type 1 (GD1) and type 3 (GD3).

Guard1

The Phase 1/2 clinical trial for GD1 (named Guard1) is enrolling in the U.S. and Canada. The trial is intended to recruit 8 to 16 individuals between the ages of 16 and 50 with GD1, including both those who are treatment-naïve and those who are stable on enzyme replacement therapy.

For more information on Guard1, click here.

Guard3

AVROBIO plans to initiate a global registrational Phase 2/3 trial for GD3, (named Guard3) in the second half of 2023, subject to regulatory alignment.

For more information on Guard3, please contact medinfo@avrobio.com.

AVROBIO’s investigational gene therapy for cystinosis is being studied in a Phase 1/2 clinical trial sponsored by the University of California, San Diego*. The trial is evaluating the safety and efficacy of this hematopoietic stem cell (HSC) gene therapy approach in adult patients affected by the most severe and common form of cystinosis who previously had been treated with the current standard of care, cysteamine. The trial is fully enrolled.

*Collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 is funded in part by grants to UCSD from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH).

For more information, click here.

AVROBIO’s investigational gene therapy for neuronopathic mucopolysaccharidosis type II (nMPSII or Hunter syndrome), is being studied in a Phase 1/2 clinical trial sponsored by the University of Manchester, U.K. The 24-month, single-arm, open label study will evaluate the gene therapy’s safety and tolerability, as well as its pharmacodynamic and clinical efficacy. The trial aims to recruit up to five patients with nMPS II who are aged between 3 and 12 months.

For more information on the trial, contact mpsiitrial@manchester.ac.uk.

AVROBIO has a preclinical research program for a gene therapy for Pompe disease. We have shown a favorable preclinical safety and efficacy profile in a mouse model of Pompe disease.